Selected article for: "control group and good safety profile"
Author: Doggrell, Sheila A.
Title: Remdesivir, a remedy or a ripple in severe COVID-19?
  • Cord-id: t18xkzms
  • Document date: 2020_9_20
    • ID: t18xkzms
    Snippet: INTRODUCTION: In clinical trial for the Ebola virus, the broad-spectrum anti-viral agent remdesivir was shown to have a good safety profile. Remdesivir is now being tested in severe COVID-19. AREAS COVERED: The Gilead Sciences SIMPLE trial suggests that the short-term use of remdesivir probably does not increase mortality dramatically or have serious short-term toxicity when used to treat severe COVID-19. The Adaptive COVID-19 treatment trials (ACTT1) trial showed that remdesivir may shorten rec
    Document: INTRODUCTION: In clinical trial for the Ebola virus, the broad-spectrum anti-viral agent remdesivir was shown to have a good safety profile. Remdesivir is now being tested in severe COVID-19. AREAS COVERED: The Gilead Sciences SIMPLE trial suggests that the short-term use of remdesivir probably does not increase mortality dramatically or have serious short-term toxicity when used to treat severe COVID-19. The Adaptive COVID-19 treatment trials (ACTT1) trial showed that remdesivir may shorten recovery and decrease mortality in severe COVID-19 without increasing adverse effects. EXPERT OPINION: It seems to me that we have learnt very little from the SIMPLE trial, and this would be predicted from a trial that has no control or placebo group. The results of ACTT1 were reported early after an interim analysis showed that a higher than expected number of recoveries had occurred. There was an indication that remdesivir may be reducing mortality, but this was no statistical significance. The trial is continuing, and the final data are eagerly awaited to determine whether remdesivir is a game-changing remedy or a ripple in the ongoing search for a medicine for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activity limitation and acute sars cov respiratory syndrome coronavirus: 1
    • acute respiratory failure and liver enzyme: 1
    • acute respiratory failure and loading dose: 1
    • acute respiratory failure and local standard: 1
    • acute respiratory failure and lopinavir chloroquine hydroxychloroquine: 1
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure common and lopinavir ritonavir: 1
    • acute respiratory syndrome and adenosine analog: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adenosine analog prodrug: 1, 2, 3
    • acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and local standard: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lopinavir chloroquine hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and adenosine analog: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and adenosine analog prodrug: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute sars cov respiratory syndrome coronavirus and loading dose: 1, 2
    • acute sars cov respiratory syndrome coronavirus and local standard: 1